Statement of Principles concerning malignant neoplasm of the oesophagus (Reasonable Hypothesis) (No. 11 of 2026)

The central concept is the “reasonable hypothesis”. Under section 120A of the VEA, a hypothesis connecting a disease or death to service is reasonable only if it fits the template of the relevant Statement of Principles and is not contrary to proven medical facts. This instrument directly provides that template. The hypothesis is raised when at least one factor in section 9 exists and is related to the person’s relevant service (section 10). The term “reasonable hypothesis” is not defined in the instrument itself, but it is well established in the veteran entitlements context as a hypothesis that is plausible, not fanciful, and supported by some probative material.

“Malignant neoplasm of the oesophagus” is defined precisely. It means a primary malignant neoplasm arising from cells of the oesophagus, with the oesophagus defined as the structure from the lower border of the hypopharynx to the lower border of the oesophageal sphincter, including the gastro-oesophageal junction. The definition expressly excludes soft tissue sarcoma, carcinoid tumour, non-Hodgkin lymphoma, and Hodgkin lymphoma. This means that if a claimant has one of these excluded cancers, the instrument does not apply, and no factor in section 9 can be used to raise a hypothesis. The ICD-10-AM code C15 is referenced for classification purposes, but the meaning of the disease is the one given in the instrument, not the code itself. This avoids conflicts if the coding changes over time.

“Relevant service” is defined in the Dictionary by reference to categories under the VEA and MRCA. It includes operational service, peacekeeping service, hazardous service, and British nuclear test defence service under the VEA, as well as warlike and non-warlike service under the MRCA. The definition does not include peacetime service under the VEA unless it falls into one of those categories. This means that many veterans who served only in peacetime Australian forces without any specific hazardous or operational deployment will not have relevant service for the purpose of this instrument. The instrument applies only to claims under section 120A of the VEA and section 338 of the MRCA; it does not apply to other compensation schemes such as the Safety, Rehabilitation and Compensation Act 1988 or the Australian workers’ compensation systems.

Other key concepts include the various quantified risk factors: pack-years (20 cigarettes per day for one year, or 7,300 grams of smoking tobacco), cumulative equivalent dose (ionising radiation to the oesophagus calculated per ARPANSA guidelines), and cumulative exposure hours for asbestos (different thresholds for enclosed versus open environments). The instrument distinguishes between squamous cell/undifferentiated carcinoma and adenocarcinoma/undifferentiated carcinoma, with separate factors for each. For example, alcohol consumption of at least 180 kilograms before clinical onset applies only to squamous cell or undifferentiated carcinoma. So a claimant with adenocarcinoma cannot rely on alcohol consumption as a factor. Similarly, Barrett oesophagus and body mass index of 30 or greater apply only to adenocarcinoma or undifferentiated carcinoma.

The primary affected persons are veterans and members of the Australian Defence Force who render relevant service and who later develop malignant neoplasm of the oesophagus. This includes veterans with operational service (e.g., service in a specified warlike operation), peacekeeping service, hazardous service (e.g., service involving exposure to nuclear radiation), or British nuclear test defence service under the VEA. It also includes members serving in warlike or non-warlike service under the MRCA. The instrument applies to their dependents and estate when death from oesophageal cancer is claimed.

The instrument also affects decision-makers within the Department of Veterans’ Affairs, the Military Rehabilitation and Compensation Commission, the Veterans’ Review Board, and the Administrative Appeals Tribunal. Those bodies must apply the factors strictly when assessing whether a reasonable hypothesis exists. They cannot accept a hypothesis that relies on a risk factor not listed in section 9, even if medical literature supports a different causal pathway. The instrument therefore constrains administrative discretion. It also binds medical advisers who prepare reports for those decision-makers. They must tailor their evidence to the specific definitions and thresholds.

Legal practitioners representing claimants and the Commonwealth will be directly affected. They must understand the interplay between the instrument’s factor list, the evidentiary standard (reasonable hypothesis), and the underlying entitlement provisions. For example, even if a factor is satisfied, section 10 requires that the factor be related to the relevant service. That might require evidence that the smoking, asbestos exposure, or other factor occurred during service, not merely that it occurred at some time in the person’s life. Inability to obtain appropriate clinical management as a factor (22) applies only to aggravation of a pre-existing condition, not to the initial onset. That nuance affects both sides of litigation.

Healthcare providers and hospitals may be indirectly affected if they are asked to provide records confirming diagnosis, histology, and date of clinical onset. They may need to report on whether the claimant had Barrett oesophagus, Plummer-Vinson syndrome, or lichen planus of the oesophagus, and when those conditions were present. The instrument may also affect epidemiological research and public health debates because the Authority’s decisions influence which exposures are officially recognised as service-related for compensation purposes. However, the instrument itself does not impose any obligation on private individuals or businesses; it is an internal rule for determining Commonwealth liability.

The Repatriation Medical Authority has the duty under section 196B(2) of the VEA to determine Statements of Principles based on sound medical-scientific evidence. In this instrument, the Authority states that it is of the view that such evidence indicates oesophageal cancer can be related to relevant service. The Authority does not have a duty to update the factors continuously, but it has done so by repealing the 2015 version. The instrument does not confer any rights on the Authority itself; it imposes an evidentiary framework.

Claimants have the right to rely on any factor in section 9 to establish a reasonable hypothesis, provided they can produce evidence that the factor exists and is related to their service. If at least one factor is satisfied, the decision-maker must accept that a reasonable hypothesis has been raised, unless there is evidence that the hypothesis is contrary to proven medical facts or that the factor is not in fact related to service. The instrument does not guarantee entitlement to a pension or compensation; it only establishes the causation element. Other criteria (e.g., incapacity, death, degree of impairment) must still be met under the VEA or MRCA.

The right to use factor 22 (inability to obtain appropriate clinical management) is restricted. It applies only to material contribution to or aggravation of a condition that was suffered or contracted before or during service but did not arise out of service. This means it cannot be used for initial onset claims. It also requires that the clinical management sought was appropriate and that the inability to obtain it predated the clinical worsening. The note to section 9 indicates that this factor is subject to section 10(2), which narrows its application further. Practitioners must ensure that the claim is correctly framed as an aggravation claim.

The Commonwealth has the right to argue that a factor does not exist because the claimant’s evidence fails to meet the instrument’s definitions. For example, if a claimant says they smoked 10 cigarettes per day for 5 years and ceased 25 years before clinical onset, the smoking factor is not satisfied because cessation occurred more than 20 years before onset. The Commonwealth can also argue that the factor is not related to service; for instance, if the asbestos exposure occurred entirely in a civilian job after service. Section 10(1) explicitly states that the factor must be related to the person’s relevant service. The instrument does not define “related to”, leaving that to the general law under the VEA and MRCA.

The instrument also creates a duty on decision-makers to consider the cross-referencing provision in section 11. If a factor refers to an injury or disease for which a separate Statement of Principles exists, then the factors in that other Statement of Principles apply. This means that if a claimant relies on factor 3 (ionising radiation) and that radiation caused another condition (e.g., thyroid cancer), the decision-maker must look to the relevant SoP for that other condition. This adds complexity.

This instrument does not itself impose penalties or create enforcement mechanisms. It is not a criminal or regulatory statute. Its function is evidentiary within the veterans’ compensation system. If a claimant provides false or misleading information to support a factor, the general penalties under Part VII of the VEA may apply. Section 208 of the VEA makes it an offence to knowingly or recklessly provide false or misleading information in relation to a claim. That offence carries a maximum penalty of 12 months imprisonment. The instrument does not create any specific offence; the existing VEA provisions apply.

Enforcement is through the standard claims investigation process. The Department of Veterans’ Affairs may require further evidence, obtain medical reports, or refer matters to the Commonwealth Director of Public Prosecutions if fraud is suspected. The Administrative Appeals Tribunal can review decisions, but it does not enforce penalties. The instrument itself provides no role for regulators or inspectors.

From a compliance perspective, the instrument increases the information burden on claimants, but that is not a penalty. If a claimant cannot produce evidence meeting the defined thresholds (e.g., cumulative asbestos hours, specific HPV strains, histology-confirmed Barrett oesophagus), the claim will fail. That failure is not a penalty in the punitive sense; it is a legal consequence of insufficient proof. However, the instrument does contain one clause that could be seen as a quasi-penalty: the exclusion of certain cancers (sarcomas, lymphomas) means that a veteran with a malignant oesophageal tumour that turns out to be a different histological type will be denied the use of this SoP even if they have the same risk factors. That is a classification lock-out, not a penalty, but it has the same practical effect of denying a causation pathway.

The instrument also does not contain any enforcement provisions regarding medical practitioners. They are not obliged to provide evidence; the onus is on the claimant. There is no mechanism to compel a doctor to calculate pack-years or cumulative radiation dose. The enforcement burden falls entirely on the claimant and the decision-maker. The Authority’s role ends once the instrument is published. There is no ongoing compliance monitoring.

The instrument interacts primarily with the VEA and the MRCA. It is made under subsection 196B(2) of the VEA and applies to claims under section 120A of the VEA and section 338 of the MRCA. This means it has no direct effect under the Safety, Rehabilitation and Compensation Act 1988, the Seafarers Rehabilitation and Compensation Act 1992, or the workers’ compensation legislation of any state or territory. Those jurisdictions operate under different causation standards and are not bound by this Statement of Principles. However, in practice, the Repatriation Medical Authority’s decisions can influence other tribunals and courts as evidence of current medical science, but that is not a legal interaction.

Section 11 of the instrument provides a specific interaction with other Statements of Principles. If a factor in section 9 refers to an injury or disease for which a separate SoP has been determined under subsection 196B(2), then the factors in that other SoP apply. For example, factor 6 refers to a caustic burn of the oesophagus. If there is an SoP for caustic burns (or for the injury caused by such burns), then that SoP’s factors must be considered. This prevents claimants from bypassing the specific requirements of the other SoP by relying solely on this instrument. Similarly, factor 19 refers to Barrett oesophagus; if there is an SoP for Barrett oesophagus, the conditions of that SoP must be satisfied as well. This cross-reference creates a cascading effect: multiple SoPs may need to be consulted in a single claim.

The instrument also interacts with the interpretation provisions of the VEA and MRCA. Definitions such as “relevant service” are drawn from those Acts. Section 5C of the VEA defines terms like “operational service” and “peacekeeping service”. The instrument does not override those definitions. It merely incorporates them by reference. The instrument also notes that “VEA” and “MRCA” are defined in its Dictionary, but those definitions simply point to the Acts as amended from time to time.

Specifically, under MRCA section 338, the standard of proof for determining whether an injury or disease is related to service is the same as under VEA section 120A. So the instrument applies identically in both contexts. However, MRCA has its own definitions of warlike and non-warlike service, which are not identical to VEA categories. This means a person whose service is classified as non-warlike under MRCA may be covered, whereas a person with peacetime service under VEA may not be, even if their exposure circumstances are similar.

The instrument repeals No. 120 of 2015, so the previous version no longer has any legal effect. This is important for pending claims: any claim not finally determined before 19 January 2026 must be assessed under the new instrument. That could change outcomes if the new version includes factors not previously available, or removes factors that were previously available. In this new version, the Authority has added several factors: inhaling asbestos (in enclosed space and open environment), pickled vegetables consumption, tetrachloroethylene exposure, Chagas’ disease megaesophagus, and the fruit/vegetable consumption factor. It also added the “inability to obtain appropriate clinical management” factor for post-onset worsening. These additions expand the range of claims that might succeed, but they also impose stricter evidentiary requirements (e.g., cumulative hours for asbestos, defined thresholds for processed meat and pickled vegetables). The repeal of the 2015 instrument also removes any factors that were present there but not included here. Practitioners should compare both instruments; the source text did not provide the 2015 version, so I cannot state what was removed. But the instrument does not mention any transitional provisions, so the general rule of immediate effect applies.

This instrument is No. 11 of 2026 and was made on 19 December 2025, with commencement on 19 January 2026. It is a stand-alone instrument that repeals and replaces the previous Statement of Principles concerning malignant neoplasm of the oesophagus (Reasonable Hypothesis) (No. 120 of 2015). The 2015 instrument had been made under both subsections 196B(2) and (8) of the VEA. The new instrument is made only under subsection 196B(2), meaning it covers only the reasonable hypothesis standard (used for initial liability decisions) and not the balance of probabilities standard (used for certain subsequent decisions under section 196B(8)). That is a notable structural change: the Authority has chosen to issue separate instruments for each standard, whereas previously a single instrument covered both. It is possible that a separate instrument under subsection 196B(8) will be issued at a later date, or that the Authority determined that the evidence did not justify a balance of probabilities standard. Either way, this instrument is explicitly limited to the lower threshold.

The instrument does not provide a detailed explanation of the changes from the 2015 version. However, a comparison of factors shows that the 2026 instrument includes several new risk factors not present in the 2015 version: asbestos exposure (factor 4, split into enclosed and open environment), tetrachloroethylene exposure, pickled vegetable consumption, processed meat consumption, inability to consume fruit and vegetables, Chagas’ disease megaesophagus, and the “inability to obtain appropriate clinical management” factor. It also added the specific HPV strain list and maté consumption. The instrument also changed the smoking factor: the 2015 version may have had different thresholds; the 2026 version sets 2.5 pack-years and cessation within 20 years. The alcohol factor remains at 180 kilograms, but only for squamous cell carcinoma. The instrument also now includes a definition for “cumulative equivalent dose” that references the ARPANSA guide as in force on 2 August 2017. This shows an intent to adopt a static version of that guide, not a dynamic reference.

The authority under which the instrument is made has not changed: it remains section 196B(2) of the VEA. The instrument is disallowable by Parliament under the Legislation Act 2003, but no disallowance is noted. The instrument was signed by Professor Terence Campbell AM as Chairperson of the Repatriation Medical Authority. There is no indication of consultation or review details. The instrument is a legislative instrument and is registered on the Federal Register of Legislation.

The source text does not mention any specific litigation or court cases. The instrument itself is a purely administrative determination; it does not report on past judicial review. However, it is well known in practice that Statements of Principles under the VEA are regularly challenged in the Administrative Appeals Tribunal and on appeal to the Federal Court. Claims for oesophageal cancer are no exception. Common issues in litigation include whether the factor was related to service, whether the definition of clinical onset was met, and whether the hypothesis was contrary to proved medical facts. The instrument’s provisions on Barrett oesophagus, for instance, have been the subject of interpretation in previous cases. But since the source does not name any cases, I cannot cite them.

This instrument will likely generate litigation concerning the new factors, particularly the asbestos exposure thresholds. The requirement of “inhaling respirable asbestos fibres in an enclosed space for at least 1,000 hours” and the separate open environment threshold of 3,000 hours could be difficult to prove. Claimants may argue that cumulative hours should include all exposures, while the Commonwealth may argue that only time during active application/removal counts. The phrase “material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled” narrows the exposure period. Litigation may also arise over the definition of “inability to obtain appropriate clinical management” - whether it covers failure of the military medical system to provide follow-up, or only civilian medical unavailability.

The instrument’s failure to include a transitional provision may also be challenged. If a claimant’s clinical onset occurred before 19 January 2026, but the claim is lodged after that date, the new instrument applies. That could work to the claimant’s disadvantage if the 2015 instrument had more favourable factors, or to the advantage if the new one adds factors. Courts have previously determined that Statements of Principles apply to claims not yet determined, but the point is often contested.

Several traps in this instrument may catch unprepared practitioners and claimants.

First, the instrument distinguishes between histological subtypes. Many factors apply only to squamous cell or undifferentiated carcinoma, and others only to adenocarcinoma or undifferentiated carcinoma. Undifferentiated carcinoma is included in both groups, but it is not clear whether a single undifferentiated carcinoma can rely on factors from both groups. The instrument lists factors 7 through 12 for squamous cell or undifferentiated, and factors 13 through 15 for adenocarcinoma or undifferentiated. A careful reading shows that “undifferentiated carcinoma” appears in both groupings, but that may be an oversight. The prudent approach is to determine the exact histology and then only use the factors explicitly assigned to that subtype. If the histology is truly undifferentiated and cannot be assigned to squamous or adenocarcinoma, both groups appear available on their face, but that could lead to conflict. This ambiguity is likely to be a point of litigation.

Second, the smoking factor has a strict 20-year cessation window. Even a heavy smoker who quit 21 years before clinical onset cannot use smoking as a factor. This is a harsh cut-off. Claimants must prove the date of smoking cessation precisely. Similarly, the smokeless tobacco factor has a 15-year cessation window. If the claimant used chewing tobacco for 5 years but quit 16 years before onset, the factor fails.

Third, the asbestos exposure factors require both a cumulative hour threshold and that the exposure occurred during specific activities (applying, removing, dislodging, cutting or drilling asbestos-containing material). Casual exposure to asbestos dust from ambient air or from wearing contaminated clothing is not covered unless it meets those activity requirements. The enclosed space threshold is 1,000 hours, which is about 25 weeks of full-time work. That may be difficult to prove with historical records.

Fourth, the alcohol factor of at least 180 kilograms before clinical onset is a very high threshold. That equals 18,000 standard drinks. If a person started drinking at age 18 and clinical onset is at age 68, they would need to average 360 grams of alcohol per day (36 drinks) for 50 years. That is extreme consumption. Most moderate drinkers will not reach this threshold. The factor is limited to squamous cell carcinoma, so adenocarcinoma claimants cannot use it.

Fifth, the “inability to consume fruit and vegetables” factor (21) requires an average of at least 200 grams per day for at least 5 consecutive years within the 25 years before clinical onset. This is not a dietary preference; it is framed as an “inability”. The language implies that the person was unable to consume that amount due to circumstances beyond their control (e.g., service conditions, poverty, illness). A claimant who simply chose not to eat vegetables may not satisfy the factor. The term “inability” suggests a constraint, not a choice. This is a potential source of contention.

Sixth, factor 22 (inability to obtain appropriate clinical management) applies only to material contribution to or aggravation of a condition that was suffered or contracted before or during service but did not arise out of service. That is a narrow category. It does not apply to initial onset. It also requires that the inability to obtain clinical management predated the clinical worsening. If the claimant received suboptimal treatment for a pre-existing oesophageal cancer, that could be used, but they must prove the appropriate management was not obtained due to service-related reasons.

Seventh, the instrument defines “processed meat product” as preserved or cured meats including ham, frankfurters, salami and bacon. It does not include other meats like fresh sausages (unless cured) or canned meats. The threshold is an average daily intake of at least 25 grams (about one slice of ham) for at least 10 years within the 25 years before clinical onset. That is a relatively low threshold, but the 10-year duration and the need to prove the intake average may be difficult.

Eighth, the tetrachloroethylene factor requires at least 1,000 hours cumulative exposure, and first exposure at least 10 years before onset. Tetrachloroethylene is a dry-cleaning solvent and degreasing agent. Exposure in military service may occur from cleaning operations, but proving cumulative hours and the timeline may be challenging.

Ninth, the instrument introduces a factor for chewing betel quid or areca nut, which is particularly relevant to veterans who served in the Pacific or South Asian regions. The factor requires use on more days than not for at least 5 years, and onset within 15 years of cessation. This factor is not limited to any histological subtype, so it can be used for any oesophageal cancer.

Tenth, the definition of “cumulative equivalent dose” uses the ARPANSA guide as in force on 2 August 2017. That is a static reference, so if ARPANSA updates its methodology, this instrument does not incorporate the update. Claimants must use the 2017 version. This could lead to discrepancies if later guides would have allowed a different calculation.

Eleventh, the factor for Barrett oesophagus (15) applies only to adenocarcinoma or undifferentiated carcinoma. But Barrett oesophagus is itself a risk factor for adenocarcinoma. The instrument requires that Barrett oesophagus be present “before clinical onset”. That means the claimant must have a diagnosis of Barrett oesophagus prior to the cancer diagnosis. It does not allow a retrospective inference that Barrett oesophagus must have existed. Medical records are essential.

Twelfth, the “inability to obtain appropriate clinical management” factor (22) could be a double-edged sword. If the veteran received any clinical management, that might be argued to be appropriate, defeating the factor. The term “appropriate” is not defined, so it will be a matter of expert opinion.

Compliance with this instrument is not a matter for businesses or the general public; it is for claimants and their representatives seeking to establish a reasonable hypothesis for a compensation claim. The first step is to determine the exact histological type of malignant neoplasm of the oesophagus from biopsy or surgical pathology reports. This is critical because the factor list is divided by subtype. If the pathology report says only “carcinoma”, further testing may be needed to classify it as squamous, adenocarcinoma, or undifferentiated. If undifferentiated, both groups of factors may arguably apply, but careful legal analysis is required.

Second, obtain a clear date of clinical onset. Clinical onset is the date when symptoms of the cancer first appear, not the date of diagnosis. The instrument repeatedly uses the phrase “before clinical onset”. Claimants need medical evidence of when symptoms (dysphagia, weight loss, etc.) began. If the date is uncertain, the claimant risks missing time windows such as the 20-year smoking cessation limit.

Third, collect evidence for each potential factor. For smoking, quantify total pack-years and date of cessation. For alcohol, calculate total grams consumed before clinical onset: 180 kilograms is 180,000 grams of pure alcohol. At 10 grams per standard drink, that is 18,000 standard drinks. The instrument notes that alcohol consumption is calculated using the Australian Standard of 10 grams per drink. Records of alcohol intake may be difficult to prove, but sworn statements and medical records of alcohol-related conditions may help.

Fourth, for asbestos exposure, document the hours of exposure in enclosed spaces and open environments separately. Records of service postings, trade qualifications, and work diaries can help. The instrument requires that the exposure occurred during application, removal, dislodging, cutting or drilling of asbestos-containing material. General proximity to asbestos without those activities is insufficient. Expert evidence from an occupational hygienist may be necessary.

Fifth, for dietary factors (processed meat, pickled vegetables, fruit/vegetable intake, maté, betel nut), the claimant must provide a reliable dietary history. The instrument specifies that the consumption must be “at least daily” for pickled vegetables and “on more days than not” for betel nut, maté, and smokeless tobacco. For processed meat, a daily average over 10 years must be shown. This may require reconstruction of dietary habits from service records, family statements, and medical notes.

Sixth, for the medical condition factors (Barrett oesophagus, Plummer-Vinson syndrome, lichen planus of the oesophagus, gastro-oesophageal reflux disease, caustic burn, Chagas’ disease megaesophagus), obtain contemporaneous medical diagnoses. These conditions must be objectively documented before clinical onset. If a condition like Barrett oesophagus was diagnosed after the cancer, it cannot be used as a factor. For gastro-oesophageal reflux disease, the instrument requires it to have been present for at least five years before clinical onset. That requires consistent medical records.

Seventh, for the ionising radiation factor, obtain records of any diagnostic or therapeutic radiation exposure or occupational exposure during service (e.g., as a radiographer or aircrew). Calculate cumulative equivalent dose using the ARPANSA guide from 2 August 2017. This is a technical calculation that may require expert assistance. The minimum dose is 0.1 sievert to the oesophagus, which is a relatively low dose (equivalent to about 10 CT scans of the chest). Even low-dose exposure can qualify if it is service-related.

Eighth, for the tetrachloroethylene factor, identify service roles that involved dry-cleaning or degreasing. Document hours of exposure. The first exposure must be at least 10 years before clinical onset, and cumulative hours at least 1,000. Hour logs or employment records are essential.

Ninth, for factor 22 (inability to obtain appropriate clinical management), the claim must be for aggravation of a pre-existing condition. The claimant must show that the oesophageal cancer was present before or during service (but not arising out of service), and that because of inability to obtain appropriate management, the condition worsened. This requires evidence that appropriate management existed and was not obtained due to service-related reasons (e.g., remote posting, lack of medical resources). The factor is not for initial onset.

Tenth, ensure that all factors relied upon are related to the person’s relevant service. This may require linking the exposure to a specific posting, operation, or incident during the defined categories of service (operational, peacekeeping, hazardous, etc.). The instrument does not require that the factor was caused by service, only that it is related to service. For example, a veteran who smoked heavily during peacetime service that is not relevant service cannot use smoking if the smoking occurred entirely in that non-relevant period. The factor must be related to the relevant service, not just to service generally.

Finally, maintain full documentation and obtain specialist legal advice. The instrument allows a claim to succeed if at least one factor exists; the claimant does not need to prove all factors. But proving even one factor to the required standard is often difficult. Engaging a medical specialist who is familiar with the SoP definitions can make the difference between acceptance and rejection.